Kisspeptin‑10 (KP‑10) is a product of the KiSS1 precursor peptide that functions as a central regulator of neuroendocrine systems.

GLP-1 RAs linked to lower risk among those with type 2 diabetes and without diabetes; greater protection seen versus metformin, insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists ...

ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers) are equally recommended as first-line treatment for cardiovascular and renal protection in clinical practice.

GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin. HealthDay News — Glucagon-like peptide 1 receptor agonists (GLP-1 ...

TUESDAY, Sept. 2, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published ...

There was a lower risk of meningioma, endometrial cancer, and ovarian cancer in patients taking GLP-1 receptor agonists. Patients who are overweight or obese may have a lower risk of developing cancer ...

Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer. (HealthDay News) — For adults with obesity, glucagon-like ...

The incidence rates of the 14 cancers were 13.6 and 16.4 per 1000 person-years, respectively, with a significantly lower overall cancer risk among GLP-1 RA users vs nonusers. HealthDay News — For ...